Palvella Therapeutics, Inc. (PVLA) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Palvella Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.397 Good day, and thank you for standing by. Welcome to Palvela's first quarter 2025 financial 00:00:04.397 -- 00:00:06.520 results and corporate update conference call. 00:00:06.520 -- 00:00:09.144 At this time, all participants are in a listen-only mode. 00:00:09.144 -- 00:00:12.028 After the speaker's presentation, there'll be a question and answer session. 00:00:12.028 -- 00:00:15.353 To ask a question during the session, you'll need to press star 11 on your telephone. 00:00:15.353 -- 00:00:18.217 You will then hear an automated message advising your hand is raised. 00:00:18.217 -- 00:00:20.941 To withdraw your question, please press star 11 again. 00:00:20.941 -- 00:00:23.384 Please be advised, today's conference is being recorded. 00:00:23.384 -- 00:00:25.447 I would now like to turn the conference over to your speaker today. 00:00:25.447 -- 00:00:28.211 Bo Hanwei, please go ahead. 00:00:28.211 -- 00:00:32.059 Thank you, operator. Good morning and thank you for joining the Palvela Therapeutics 00:00:32.059 -- 00:00:36.244 Q1 2025 financial results and corporate update call. 00:00:36.244 -- 00:00:40.710 As a reminder, our press release summarizing today's updates is available under the investor 00:00:40.710 -- 00:00:44.352 section of our website at www.palvelatx.com. 00:00:45.796 -- 00:00:50.843 On today's call, we are joined by Wes Coffinan, our chief executive officer, Jeff Martini, 00:00:50.843 -- 00:00:56.707 our chief scientific officer, and Matt Korenberg, our chief financial officer. 00:00:57.288 -- 00:01:01.394 Before we begin, please note that today's remarks may include forward-looking statements 00:01:01.394 -- 00:01:05.900 regarding our development programs, regulatory plans, commercial outlook, and financial 00:01:05....